Teva, Actavis and Mylan launch generic Celebrex capsules in USA

10 December 2014

Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) said today that it has launched the first US Food and Drug Administration-approved generic equivalent to pharma giant Pfizer’s (NYSE: PFE) blockbuster drug Celebrex (celecoxib) capsules in the USA.

The news was quickly follow by an announcement from Ireland-headquartered generics major Actavis (NYSE: ACT), saying that it too was debuting its generic Celebrex in the USA. Adding to this, Mylan (Nasdaq: MYL) also stated that it had launched a copy version of the drug. All three companies are offering 50, 100, 200, and 400mg strengths of celecoxib.

“Teva is pleased to be the first to launch generic Celebrex. The addition of Celecoxib Capsules to our US generics portfolio is further evidence of Teva’s commitment to bring affordable treatment solutions to patients,” said Siggi Olafsson, president and chief of Global Generic Medicines at Teva.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK